# US 2022/0025030 A1 · Human antibodies to human delta like ligand 4

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0025030 A1
- Document ID: US20220025030A1
- Status: Published application
- Kind: A1
- Application number: 16/892,336
- Filed: 2020-06-04
- Published: 2022-01-27
- Earliest claimed: 2006-12-14
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Nicholas J. Papadopoulos; Joel H. Martin; Eric Smith; Irene Noguera-Troise; Gavin Thurston
- Web page: https://patentgrep.com/patent/US20220025030A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/18: against material from animals or humans
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/30: characterized by aspects of specificity or valency
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The anti-hDll4 antibody or fragment thereof of the present invention have a high affinity with the KD of 500 pM or less, as measured by surface plasmon resonance.

## Claims

### Claim 1

A method of treating, ameliorating, or inhibiting tumor growth or cancer, comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or fragment thereof that specifically binds human delta-like ligand 4 (Dll4) and blocks Dll4-Notch signal pathways, such that the tumor growth or cancer is treated, ameliorated, or inhibited, wherein the antibody or fragment thereof comprises a heavy chain variable region (HCVR) comprising heavy chain CDR1, CDR2 and CDR3 sequences of SEQ ID NOS:431, 433 and 435, respectively, or a light chain variable region (LCVR) comprising light chain CDR1, CDR2 and CDR3 sequences of SEQ ID NOS:439, 441 and 443, respectively.

### Claim 2 (depends on 1)

The method of claim 1, wherein the antibody or fragment thereof comprises a HCVR comprising the amino acid sequence of SEQ ID NO:429 or 901.

### Claim 3 (depends on 1)

The method of claim 1, wherein the antibody or fragment thereof comprises a LCVR comprising the amino acid sequence of SEQ ID NO:437 or 903.

### Claim 4 (depends on 1)

The method of claim 1, wherein the antibody or fragment thereof comprises heavy chain CDR1, CDR2 and CDR3 sequences of SEQ ID NOS:431, 433 and 435, respectively, and light chain CDR1, CDR2 and CDR3 sequences of SEQ ID NOS:439,441 and 443, respectively.

### Claim 5 (depends on 4)

The method of claim 4, wherein the antibody or fragment thereof comprises a HCVR comprising the amino acid sequence of SEQ ID NO:429 or 901.

### Claim 6 (depends on 4)

The method of claim 4, wherein the antibody or fragment thereof comprises a LCVR comprising the amino acid sequence of SEQ ID NO:437 or 903.

### Claim 7

A method of treating, ameliorating, or inhibiting tumor growth or cancer, comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or fragment thereof that specifically binds human delta-like ligand 4 (Dll4) and blocks Dll4-Notch signal pathways, such that the tumor growth or cancer is treated, ameliorated, or inhibited, wherein the antibody or fragment thereof comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:429 or 901, and a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:437 or 903.

### Claim 8 (depends on 7)

The method of claim 7, wherein the antibody or fragment thereof comprises a HCVR/LCVR combination of SEQ ID NO:429/437 or SEQ ID NO:901/903.

### Claim 9

A method of treating, ameliorating, or inhibiting pathological angiogenesis, comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or fragment thereof that specifically binds human delta-like ligand 4 (Dll4) and blocks Dll4-Notch signal pathways, such that the pathological angiogenesis is treated, ameliorated, or inhibited, wherein the antibody or fragment thereof comprises a heavy chain variable region (HCVR) comprising heavy chain CDR1, CDR2 and CDR3 sequences of SEQ ID NOS:431, 433 and 435, respectively, or a light chain variable region (LCVR) comprising light chain CDR1, CDR2 and CDR3 sequences of SEQ ID NOS:439, 441 and 443, respectively.

### Claim 10 (depends on 9)

The method of claim 9, wherein the antibody or fragment thereof comprises a HCVR comprising the amino acid sequence of SEQ ID NO:429 or 901.

### Claim 11 (depends on 9)

The method of claim 9, wherein the antibody or fragment thereof comprises a LCVR comprising the amino acid sequence of SEQ ID NO:437 or 903.

### Claim 12 (depends on 9)

The method of claim 9, wherein the antibody or fragment thereof comprises heavy chain CDR1, CDR2 and CDR3 sequences of SEQ ID NOS:431, 433 and 435, respectively, and light chain CDR1, CDR2 and CDR3 sequences of SEQ ID NOS:439,441 and 443, respectively.

### Claim 13 (depends on 12)

The method of claim 12, wherein the antibody or fragment thereof comprises a HCVR comprising the amino acid sequence of SEQ ID NO:429 or 901.

### Claim 14 (depends on 12)

The method of claim 12, wherein the antibody or fragment thereof comprises a LCVR comprising the amino acid sequence of SEQ ID NO:437 or 903.

### Claim 15

A method of treating, ameliorating, or inhibiting pathological angiogenesis, comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or fragment thereof that specifically binds human delta-like ligand 4 (Dll4) and blocks Dll4-Notch signal pathways, such that the pathological angiogenesis is treated, ameliorated, or inhibited, wherein the antibody or fragment thereof comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:429 or 901, and a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:437 or 903.

### Claim 16 (depends on 15)

The method of claim 15, wherein the antibody or fragment thereof comprises a HCVR/LCVR combination of SEQ ID NO:429/437 or SEQ ID NO:901/903.
